Esther Fernandez-Galan
Overview
Explore the profile of Esther Fernandez-Galan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
83
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sainz de Medrano J, Laguna J, Julian J, Filella X, Fabregat A, Luquin M, et al.
Scand J Clin Lab Invest
. 2025 Feb;
:1-9.
PMID: 39954248
ProGRP (Progastrin-releasing peptide), SCC (Squamous Cell Carcinoma Antigen), and HE4 (Human epididymis protein 4) are serum tumor markers (STMs) frequently used in clinical practice, particularly for detection and monitoring of...
2.
Portoles I, Ribera J, Fernandez-Galan E, Lecue E, Casals G, Melgar-Lesmes P, et al.
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612527
RNA helicase DHX15 plays a significant role in vasculature development and lung metastasis in vertebrates. In addition, several studies have demonstrated the overexpression of DHX15 in the context of hepatocellular...
3.
Trape J, Fernandez-Galan E, Auge J, Carbonell-Prat M, Filella X, Miro-Canis S, et al.
Tumour Biol
. 2024 Mar;
46(s1):S35-S63.
PMID: 38517826
Background: Tumor markers (TMs) are a heterogeneous group of molecules used in the diagnosis, prognosis and follow-up of cancer patients. During neoplastic differentiation, cells can either directly synthesize or induce...
4.
Fernandez-Galan E, Sandalinas S, Macias-Munoz L, Portoles I, Ribera J, Morales-Romero B, et al.
Adv Lab Med
. 2023 Dec;
4(3):227-235.
PMID: 38075172
No abstract available.
5.
Fernandez-Galan E, Sandalinas S, Macias-Munoz L, Portoles I, Ribera J, Morales-Romero B, et al.
Adv Lab Med
. 2023 Dec;
4(3):218-226.
PMID: 38075169
Objectives: Chronic liver disease and related complications, cirrhosis and hepatocellular carcinoma, are associated with high mortality. Curative treatments, partial hepatectomy or liver transplantation, have limited applicability in patients with cirrhosis...
6.
Filella X, Rodriguez-Garcia M, Fernandez-Galan E
Clin Chem Lab Med
. 2022 Nov;
61(5):895-905.
PMID: 36394981
Tumor markers are a heterogeneous group of substances released by cancer cells into bloodstream, but also expressed by healthy tissues. Thus, very small concentrations can be present in plasma and...
7.
Carreras-Dieguez N, Glickman A, Munmany M, Casanovas G, Agusti N, Diaz-Feijoo B, et al.
Diagnostics (Basel)
. 2022 Jan;
12(1).
PMID: 35054393
(1) OBJECTIVE: To assess the performance of CA125, HE4, ROMA index and CPH-I index to preoperatively identify epithelial ovarian cancer (EOC) or metastatic cancer in the ovary (MCO). (2) METHODS:...
8.
Glickman A, Paredes P, Carreras-Dieguez N, Ninerola-Baizan A, Gaba L, Pahisa J, et al.
Eur Radiol
. 2021 Sep;
32(4):2200-2208.
PMID: 34586465
Objectives: Accurate assessment of disease extent is required to select the best primary treatment for advanced epithelial ovarian cancer patients. Estimation of tumour burden is challenging and it is usually...
9.
Fernandez-Galan E, Badenas C, Fondevila C, Jimenez W, Navasa M, Puig-Butille J, et al.
Liver Transpl
. 2021 Aug;
28(2):257-268.
PMID: 34407295
Monitoring of graft function is essential during the first months after liver transplantation (LT), but current liver function tests (LFTs) lack the specificity and sensitivity to ensure an efficient diagnosis...
10.
Gonzalez-de-la-Presa B, Fernandez-Bonifacio R, Fernandez-Galan E, Mares L, Munoz R, Parra-Robert M, et al.
Toxicol Mech Methods
. 2020 May;
30(6):450-453.
PMID: 32375552
6-Monoacetylmorphine (6-MAM) is a specific metabolite of heroin. Thus, the presence of 6-MAM in urine is a definitive indication of heroin intake. The possibility of having an immunoassay procedure to...